CrossrefInfokarte
From Therapeutic Nihilism to Precision Hepatology: Resmetirom and Semaglutide as Catalysts for a New Era in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Management
Livers · 2026-11-06 · 6 (6) · 116
DOI: 10.3390/livers6060116 ↗Abstract
The publication of the joint EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy represents a watershed moment in hepatology [...]
EUVIMED